HER2-Negative/HR+ and Triple Negative Breast Cancer-Global Drug Forecast and Market Analysis to 2025: ken Research

Human epidermal growth factor receptor type 2 (HER2-) breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. HER2-negative breast cancer can be subdivided into hormone receptor-positive (HER2-/HR+), and triple negative breast cancer (TNBC). The prognoses of HER2-/HR+ and TNBC differ dramatically, as patients with TNBC progress more rapidly towards metastatic disease and only respond to chemotherapy agents. A large number of pipeline agents are being developed in HER2-/HR+ and/or TNBC, and are likely to change the treatment paradigm for these patients.

Global Breast Cancer Drug Market Research

This report highlights the significant unmet need for expansion in the HER2- breast cancer marker across the eight major markets; it also discusses the associated commercial opportunities for new market entrants to gain a foothold in the market. GlobalData anticipates the HER2- breast cancer market to almost double, from $5.43B to $10.58B, over the forecast period of 2015-2025. The key drivers will be the incorporation of CDK4/6 inhibitors into the first-line metastatic setting and the rise of new targeted therapies and immunotherapies.

Key Findings

In 2015, the value of the HER2- breast cancer market in the 8MM was estimated to be $5.43B. This is forecast to grow to $10.58B by the end of the forecast period, with China the main driver of growth.

The largest driver will be the incorporation of premium priced CDK4/6 inhibitors into the first line setting. Pfizer’s Ibrance and Novartis’ ribociclib are expected to each reach blockbuster status by the end of the forecast period.

However, patent expiries of several blockbuster drugs and pricing difficulties are expected to limit growth in the HER2- breast cancer market over the forecast period.

Large market opportunities remain for the development of novel therapies in patients who acquire resistance to endocrine therapy.

Key topics covered in report

Prognosis for Breast Cancer

Triple Negative Breast Cancer

Global Breast Cancer Drug Forecast

Molecular Subtypes of Breast Cancer

Global Breast Cancer Drug Market Size

Global Breast Cancer Drug Market Share

Global Breast Cancer Drug Market Analysis

Global Breast Cancer Drug Market Research

For more coverage click on the link below:

https://www.kenresearch.com/healthcare/pharmaceuticals/pharmapoint-her2-negative-hr-triple-negative-breast-cancer/91671-91.html

Contact Us:

Ken Research

Ankur Gupta, Head Marketing & Communications

Ankur@kenresearch.com

+91-9015378249

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s